|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
31 St James Ave, Sixth Floor, Boston, Massachusetts 02116, US
|
|
Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion’s product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.
|
Cardurion Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Cardurion Pharmaceuticals email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Cardurion Pharmaceuticals customer service number in your country click here to find.
Jennifer Lassiter is the CEO of Cardurion Pharmaceuticals. To contact Jennifer Lassiter email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.